1: Wang TH, Aung T, Lu DW, George R, Senthil S, Lu F, Odani-Kawabata N, Park KH. Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial. Clin Ophthalmol. 2024 Jul 16;18:2093-2106. doi: 10.2147/OPTH.S465369. 2: Horikiri K, Taketomi Y, Kondo K, Yamasoba T, Murakami M. Activation of the PGE2-EP2 pathway as a potential drug target for treating eosinophilic rhinosinusitis. Front Immunol. 2024 Jul 1;15:1409458. doi: 10.3389/fimmu.2024.1409458. 3: Inoue K, Shiokawa M, Kunimatsu-Sanuki S, Kang J, Uraki T, Tomita G, Ishida K. Three-year efficacy and safety of omidenepag isopropyl in patients with normal tension glaucoma. Jpn J Ophthalmol. 2024 May;68(3):206-210. doi: 10.1007/s10384-024-01052-8. Epub 2024 Apr 8.
合成参考文献
摘要:Kleemann A., Kutscher B., Reichert D., Bossart M., Pharmaceutical Substances, Thieme [Online], Stuttgart, (2025). 参考文献:10.1358/dot.2019.55.6.2984806 摘要:Ferro Desideri L, Cutolo CA, Barra F, Ferrero S, Traverso CE. Omidenepag isopropyl for the treatment of glaucoma and ocular hypertension. Drugs Today (Barc). 2019 Jun;55(6):377–84. doi: 10.1358/dot.2019.55.6.2984806.